A new disease without a known cause
From 1981, physicians in the United States began reporting clusters of patients, mostly young gay men, developing rare infections and cancers associated with a collapsing immune system, a pattern with no identified cause. Establishing what pathogen, if any, was responsible became an urgent question over the following two years, pursued simultaneously by research groups who did not know whether they were chasing the same target or different ones. The claim that eventually emerged from this period was that a single retrovirus, a type of virus that inserts its genetic material into the host cell’s DNA, was responsible for progressively destroying the immune cells needed to fight infection, and that this same virus explained cases on both sides of the Atlantic despite being isolated and named independently by separate teams.
Paris isolates LAV
In May 1983, a team at the Institut Pasteur in Paris led by Luc Montagnier and Françoise Barré-Sinoussi reported isolating a retrovirus from a lymph node sample taken from a patient at risk of AIDS, which they named lymphadenopathy-associated virus, or LAV. Their approach relied on detecting the enzyme reverse transcriptase, a marker of retroviral activity, in cultures of the patient’s lymphocytes, and observing that the virus killed the T cells it infected. This was one of the earliest concrete isolations of a candidate causative agent for the syndrome, though at the time its precise relationship to AIDS more broadly, and to similar isolates other laboratories were beginning to describe, was not yet established with certainty.
Bethesda isolates HTLV-III
A year later, in May 1984, Robert Gallo’s laboratory at the United States National Institutes of Health reported isolating a virus from AIDS patients that it named human T-cell lymphotropic virus type III, or HTLV-III, situating it as a relative of two previously known human retroviruses Gallo’s lab had itself helped discover. A third designation, AIDS-associated retrovirus or ARV, emerged from further research around August 1984 at a separate laboratory. For a period, three named viruses circulated in the scientific literature without formal confirmation that they were the same agent, a situation that mattered practically because whoever identified the virus stood to control the patent on any resulting diagnostic blood test.
One virus, several names
Direct genetic and immunological comparison, completed by January 1985, showed that LAV, HTLV-III and ARV were the same virus, ending the substantive scientific question even as the naming and credit dispute continued. The scientific community adopted a single standardised name, human immunodeficiency virus or HIV, in May 1986, retiring the three earlier, competing labels. What the comparison could not settle to everyone’s satisfaction was priority: whether Gallo’s isolate had derived, deliberately or through cross-contamination, from a sample the Pasteur group had sent him, a question that shaped years of dispute over both scientific credit and commercial patent rights to the antibody test used to screen blood donations.
Credit, contested
The priority dispute was ultimately resolved diplomatically rather than scientifically, through a 1987 agreement between the French and American governments that split credit and patent royalties between the two research institutions, an outcome reached by negotiation rather than by any further experiment settling who isolated the virus first. The scientific consequence of identification, regardless of who received credit, was concrete and fast-moving: once the virus was characterised, reliable antibody tests could be developed to screen donated blood, and understanding the virus’s biology guided the antiretroviral drug development that followed. When the Nobel Prize in Physiology or Medicine was finally awarded for the discovery in 2008, it went to Montagnier and Barré-Sinoussi alone, a decision that left Gallo’s role in the wider recognition unresolved even after the 1987 settlement had split the material stakes.
What the identification made possible
This is worth reading closely for what it shows about how scientific credit actually gets allocated when two well-resourced, well-connected laboratories reach closely related results within a year of each other and a great deal, in patents and prestige, rides on the outcome. It resists the tidy version of the story, where one lab clearly discovered the virus and the other merely followed, and instead shows overlapping isolations, disputed samples, and a resolution driven as much by government negotiation as by further experiments. Readers who want the full detail of how retroviruses are isolated in culture, or how the antibody test itself works, will need to look further, but for understanding why the Montagnier-Gallo dispute still gets mentioned decades later, the outline here is enough.